Kiniksa Pharmaceuticals 3Q 2026: Revenue $285.97M, Net income $47.35M, EPS $0.56— 10-Q Summary
Kiniksa Pharmaceuticals reported Q3 2026 revenue of $285.97M, up 58.1% YoY, with net income of $47.35M and EPS of $0.56. Growth was driven by increased ARCALYST usage. The company also began a Phase 3 trial for KPL-387 and expects results in H2 2027.
How this was made
The 30-second read
Why it matters
The earnings beat may trigger short‑term buying pressure, but long‑term performance hinges on clinical trial outcomes.
Market read
Strong quarterly results provide a fresh catalyst for the stock, with potential upside for biotech‑focused investors.
What to watch
Upcoming Phase 3 trial results for KPL-387 could significantly alter future valuation.
Background
Kiniksa Pharmaceuticals International plc filed its Q3 2026 10‑Q, highlighting revenue and profit growth.
Ticker impact
Q3 2026 revenue rose 58.1% to $285.97M and net income jumped to $47.35M, driven by higher ARCALYST sales.
upward pressure as investors price in higher sales and profit growth
The company reported a significant YoY revenue increase and a 156.8% rise in net income, indicating strong operational performance.
Market effects
Biotech sector may see renewed interest as a small-cap pharma shows strong earnings growth.
U.S. biotech investors could react positively, modest impact on broader market.
Limited to investors tracking niche pharma and rare disease treatments.
Counterpoint
If the revenue growth is not sustainable without continued ARCALYST uptake, the stock could face a pullback.
Key entities
- companyKiniksa Pharmaceuticals International plc
Biopharmaceutical company developing treatments for rare diseases.
